Market Overview:
The global hydromorphone market is expected to grow at a CAGR of 3.8% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of chronic pain, increasing number of opioid prescriptions and growing demand for abuse-deterrent formulations (ADFs). The oral segment is expected to dominate the global hydromorphone market during the forecast period, owing to its ease of use and lower side effects as compared to other forms such as injection. In terms of application, hospitals are expected to account for a major share in the global hydromorphone market due by their large patient population suffering from chronic pain. However, drug stores are also anticipated to witness significant growth during the forecast period owingto an increase in demand for prescription drugs over OTC drugs.
Product Definition:
Hydromorphone is a opioid analgesic that is used to treat moderate to severe pain. It can also be used for preoperative medication and for the relief of dyspnea associated with pulmonary edema.
Oral:
Oral is a drug that is administered by mouth as opposed to intravenously. It's effects are felt more quickly than Hydromorphone, which has an onset of up to 45 minutes after administration and a duration of approximately 4 hours.
The usage rate for oral hydromorphone in the U.
Injection:
Injection is a method used to administer drugs that are not absorbed by the body and are administered intravenously. Injectables can be sub-divided into sterile injectable solutions, pre-filled syringes, auto-injectors or pen injectors. The most commonly used injectables in the U.
Application Insights:
Based on the application, the global market is segmented into hospital, drug store and others. The hospital held a leading share of over 70% in 2017 owing to its primary use in pain management treatment. Hydromorphone is primarily used for pain management during surgeries or dental treatments and other medical procedures that require anesthesia. It has fewer side effects as compared to other opioids such as morphine which makes it suitable for long term usage in hospitals.
The growing prevalence of chronic pain disorders and rising awareness about these disorders are some of the major factors driving the demand from this segment.
Regional Analysis:
Asia Pacific held the largest market share of over 40% in 2017. The region is expected to maintain its dominance throughout the forecast period owing to increasing demand for opioid-based painkillers coupled with rising incidences of chronic pain. China, India, and Australia are among the top importers of hydromorphone from North America. In addition, new players are entering this lucrative market on a large scale by acquiring established companies or setting up their own facilities in these countries owing to low production costs and high demand for such medicines as compared to other developed nations globally.
The Middle East & Africa is anticipated to witness significant growth during the forecast period due to growing awareness about treatment options along with rising government initiatives & programs pertaining towards improving healthcare infrastructure in this region at a domestic level will help boost economic development which will further drive regional product consumption over next seven years (2030).
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace and this is expected to drive the demand for hydromorphone in the coming years.
- Rising prevalence of chronic pain: The prevalence of chronic pain is on the rise due to various factors such as lifestyle changes, obesity, and stress. This is likely to boost the demand for hydromorphone in the near future.
- Growing awareness about pain management therapies: There has been a growing awareness about various pain management therapies in recent years, which is likely to fuel the demand for hydromorphone in coming years.
- Technological advancements in drug delivery systems: There have been significant advancements in drug delivery systems over the past few years, which is expected to promote growth of the hydromorphone market over next few years. 5) Availability of generic versions of branded drugs: The availability of generic versions of branded drugs has resulted in lower prices for these drugs and this trend is likely to continue into future, thereby propelling growth prospects forthehydromorphonemarket
Scope Of The Report
Report Attributes
Report Details
Report Title
Hydromorphone Market Research Report
By Type
Oral, Injection
By Application
Hospital, Drug Store
By Companies
Purdue Pharma, Akorn, Barr Pharmaceuticals, Pfizer, Watson Laboratories, Mallinckrodt, Teva Pharmaceuticals, KV Pharmaceutical, Lannett, Apotex, Fresenius, Johnson and Johnson, Mundipharma, Novartis, Stada Arzneimittel, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
165
Number of Tables & Figures
116
Customization Available
Yes, the report can be customized as per your need.
Global Hydromorphone Market Report Segments:
The global Hydromorphone market is segmented on the basis of:
Types
Oral, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Store
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Purdue Pharma
- Akorn
- Barr Pharmaceuticals
- Pfizer
- Watson Laboratories
- Mallinckrodt
- Teva Pharmaceuticals
- KV Pharmaceutical
- Lannett
- Apotex
- Fresenius
- Johnson and Johnson
- Mundipharma
- Novartis
- Stada Arzneimittel
- Mylan
Highlights of The Hydromorphone Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- By Application:
- Hospital
- Drug Store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hydromorphone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hydromorphone is a narcotic analgesic medication used to treat moderate to severe pain. It is also used as an adjunct to opioid therapy in people who are tolerant to or cannot use opioids effectively. Hydromorphone works by reducing the perception of pain and can be taken by mouth, injection, or inhalation.
Some of the major companies in the hydromorphone market are Purdue Pharma, Akorn, Barr Pharmaceuticals, Pfizer, Watson Laboratories, Mallinckrodt, Teva Pharmaceuticals, KV Pharmaceutical, Lannett, Apotex, Fresenius, Johnson and Johnson, Mundipharma, Novartis, Stada Arzneimittel, Mylan.
The hydromorphone market is expected to register a CAGR of 3.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hydromorphone Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hydromorphone Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hydromorphone Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hydromorphone Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hydromorphone Market Size & Forecast, 2018-2028
4.5.1 Hydromorphone Market Size and Y-o-Y Growth
4.5.2 Hydromorphone Market Absolute $ Opportunity
Chapter 5 Global Hydromorphone Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Hydromorphone Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Hydromorphone Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Hydromorphone Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drug Store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hydromorphone Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hydromorphone Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Hydromorphone Analysis and Forecast
9.1 Introduction
9.2 North America Hydromorphone Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Hydromorphone Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Hydromorphone Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drug Store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Hydromorphone Analysis and Forecast
10.1 Introduction
10.2 Europe Hydromorphone Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Hydromorphone Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Hydromorphone Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drug Store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Hydromorphone Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Hydromorphone Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Hydromorphone Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Hydromorphone Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drug Store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Hydromorphone Analysis and Forecast
12.1 Introduction
12.2 Latin America Hydromorphone Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Hydromorphone Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Hydromorphone Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drug Store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Hydromorphone Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Hydromorphone Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Hydromorphone Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Hydromorphone Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drug Store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hydromorphone Market: Competitive Dashboard
14.2 Global Hydromorphone Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Purdue Pharma
14.3.2 Akorn
14.3.3 Barr Pharmaceuticals
14.3.4 Pfizer
14.3.5 Watson Laboratories
14.3.6 Mallinckrodt
14.3.7 Teva Pharmaceuticals
14.3.8 KV Pharmaceutical
14.3.9 Lannett
14.3.10 Apotex
14.3.11 Fresenius
14.3.12 Johnson and Johnson
14.3.13 Mundipharma
14.3.14 Novartis
14.3.15 Stada Arzneimittel
14.3.16 Mylan
